Advancing Early Detection of Lung Cancer: A Call to Action

Healthcare professional discussing lung health with a patient.

Understanding the Impact of Lung Cancer

Lung Cancer Diagnosis

1 in 6 Americans are diagnosed with lung cancer.

1
in
0

Mortality and Prevalence

In 2020, cancer claimed 10 million lives worldwide, with lung cancer accounting for nearly 20% of these fatalities - more than any other cancer.

Lung cancer is a devastating diagnosis affecting one in six Americans and remains the leading cause of cancer deaths in the U.S. Its toll surpasses that of colorectal, pancreatic, breast, and prostate cancers combined. Early detection is crucial, with screenings available, recommended, and often covered by Medicare and most private insurers for high-risk individuals over 50, smokers, and those exposed to occupational hazards.

The Importance of Lung Cancer Screenings

Screening Rates

Only 5.8% of the eligible 14.2 million people have been screened for lung cancer as of 2021, pointing to a significant gap in preventive healthcare.

Despite the availability of lifesaving screenings, only 6% of high-risk individuals undergo annual tests. The barriers to screening include:

  • Lack of awareness about personal risk factors

  • No primary care physician to provide referrals

  • Uncertainty regarding insurance coverage

  • Being uninsured or underinsured

  • Misconceptions about the necessity of screenings

  • Confusion about where to get screened

Additionally, current screening criteria based on age and smoking history exclude many who might still be at risk due to genetic, biological, or environmental factors. Broadening these criteria could significantly enhance early detection and save lives.

Cizzle Bio, Inc.'s Commitment to Early Detection

At Cizzle Bio, Inc., we are pioneering efforts to improve early lung cancer detection with our innovative CIZ1B biomarker test. This advanced diagnostic tool detects lung cancer at its earliest stages, offering a vital opportunity for early intervention and treatment. Our research is focused on incorporating a wider array of risk factors, beyond the conventional criteria.

We collaborate with top research institutions and healthcare providers to keep our diagnostic methods at the cutting edge of technology. Our mission is to make early detection more accessible and inclusive, potentially saving countless lives through timely diagnosis and treatment.

Get Involved and Stay Informed

For more information about our groundbreaking work and how you can benefit from early lung cancer detection, visit The Science page of our website and connect with us on LinkedIn.

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next
Next

Lung Cancer Screening: An Essential Guide